Efgartigimod Alfa and Vorhyaluronidase Alfa (Genetical Recombination) 5mL, 1,400 units

Sole-source notice

Japanese title: エフガルチギモドアルファ(遺伝子組換え)・ボルヒアルロニダーゼアルファ(遺伝子組換え)5mL/ 本1,400本

Medical
About this page
This page is based on the official tender notice and presents information processed, translated, and edited by JBid.

Overview

Procurement of 1,400 units of Efgartigimod Alfa and Vorhyaluronidase Alfa, both genetically recombined pharmaceuticals, in 5mL syringes by Nagasaki University Hospital. The contract is planned as a single tendering procedure due to absence of competition for technical reasons. The expected contract award date is November 3, 2026.

Key Details

  • Source: Kanpo
  • Notice type: Sole-source notice
  • Publication date: October 13, 2026
  • Procuring entity:
  • Planned contract date: November 3, 2026
  • Intended vendor: Kyushu Toho Co., Nagasaki Sales Office
  • Status: Active
  • Technology relevance: Possible
  • Business-action likelihood: Low – Single tendering due to absence of competition for technical reasons and a sole named vendor limit business action opportunities.

Official Notice

Official Source

Kanpo, Japan's official government gazette, in which legally required public procurement notices are formally published.

  • Source: Kanpo, Government Procurement Notice Edition
  • Official category: Sole-source procurement notice
  • Publication date: October 13, 2026
  • Publication: Kanpo, pages 51

Full English Translation

The following English translation was prepared from the original Japanese notice published in Kanpo. Where an official English summary appears in the Kanpo publication, it was used only for verification; the translation below is based on the Japanese source text.

Notice of single tendering procedures is hereby published as follows. Date: October 13, 2026. Procuring entity: Nagasaki University (National University Corporation), Director Nagayasu Yasutake. Procurement agency number: 415. Location number: 42.
1. Procurement details:
(1) Product classification number: 4
(2) Purchase subject and quantity: Efgartigimod Alfa (genetically recombined) and Vorhyaluronidase Alfa (genetically recombined) 5mL / 1,400 units.
2. Scheduled date of single tender contract:
November 3, 2026.
3. Reason for single tendering under the Agreement on Government Procurement:
b) Absence of competition for technical reasons.
4. Name of the party planned for single tender contract:
Kyushu Toho Co., Nagasaki Sales Office.
5. Responsible department:
Nagasaki University Hospital Accounting and Procurement Division, Medical Materials Section, YAMAGUCHI Yusuke, 1-7-1 Sakamoto, Nagasaki City 852-8501, Tel: 095-819-7756.
Show original Japanese notice

随意契約に関する公示

次のとおり随意契約について公示します。令和8年10月13日国立大学法人長崎大学長永安武◎調達機関番号415 ◎所在地番号42〇第4号1 調達内容(1)品目分類番号　4(2)購入等件名及び数量　エフガルチギモドアルファ(遺伝子組換え)・ボルヒアルロニダーゼアルファ(遺伝子組換え)5mL/ 本1,400本2 随意契約の予定日　令和8年11月3日3 随意契約によることとする「政府調達に関する協定」の規定上の理由 b「技術的理由による競争の不存在」4 随意契約を予定している相手方の名称　九州東邦株式会社長崎営業所5 担当部門 〒852-8501　長崎市坂本1-7- 1長崎大学病院経理調達課医療材料担当山口雄介　電話095-819-7756

Business Signal

Business Relevance

Use this notice for preparation or market research; it does not establish an open opportunity to submit a bid now.

  • Product fit: Potential
  • Current-case feasibility: Not applicable
  • Evidence confidence: Low
  • Supply-chain security: Unknown

Participation fit

This procedure is classified as sole-source and is not an open competitive tender. Direct participation is not applicable, but the notice may indicate existing government demand and active relevant vendors in Japan.

This page is based on the official Kanpo tender notice, with translation and a preliminary business assessment by I.J. Do. The official Japanese notice and tender documents are binding.

JBid is a beta technology-procurement intelligence service by I.J. Do.

Back to daily list